Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference, with President and ...

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

Creative Biolabs expands its research capabilities, offering diversified tools and services to support global biomedical innovation. SHIRLEY, NY, UNITED STATES, February 27, 2026 /EINPresswire.com/ — ...

Market expansion in med derm cross over: Almirall’s Seysara (sarecycline) won NMPA approval for moderate to severe acne (≥9 years), with China commercial launch targeted for 2026 – relevant to ...

Supa Nova by Chanté Timothy, a graphic novel about a young Black girl with a love for science, won the children’s fiction category and inaugural children’s choice prize ...

A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted ...

Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

-- The unmet need and current treatment landscape for GA -- The mechanism of disease and role of C1q -- Vonaprument, Annexon's neuroprotective C1q inhibitor with the potential to be the first targeted ...

“ In a Landscape: Classical Music in the Wild,” the outdoor classical music series known for staging piano concerts in natural and scenic settings, has released an early look at its upcoming tour.

Geographic atrophy (GA) is a severe form of age-related macular degeneration with limited treatment options, affecting millions worldwide. Recent FDA-approved therapies, pegcetacoplan and avacincaptad ...